Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria
2016-07-12 · AKARI Therapeutics · original akaritx.com ↗
NEW YORK and LONDON, July 12, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan drug designation for Coversin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Coversin, Akari’s lead clinical product, is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). Click here for full press release
The release as fetched from its publisher. akaritx.com ↗